STAT6 degraders are emerging as a promising approach for modulating IL-4/IL-13-driven inflammation in diseases such as atopic dermatitis and asthma. This whitepaper showcases BioDuro’s integrated biology platform for the systematic evaluation of STAT6 PROTACs, using Kymera I-1 as the primary benchmark. The platform spans target degradation, mechanism of action, functional activity, selectivity, and in vivo pharmacology, providing a comprehensive framework for characterizing STAT6 degrader performance and supporting informed program decisions.

• STAT6 Degradation Profiling – Quantitative assessment across cell lines and primary immune cells
• Mechanism & Target Engagement – Evaluation of STAT6 binding, CRBN engagement, and ternary-complex formation
• Functional & Selectivity Assessment – Profiling of IL-4/IL-13 pathway activity and STAT-family and CRBN-neosubstrate selectivity
•  In Vivo Pharmacology – Evaluation in OXA-induced atopic dermatitis and HDM-induced allergic asthma models

Download the full whitepaper to see how our integrated platform can accelerate your STAT6 degrader development.